Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, UTAH MEDICAL PRODUCTS INC reported revenue of $39M, down 5.8% year over year. Operating margin was 29.6% and net margin 29.3%, on a free-cash-flow margin of 37.2% with capital expenditure at 1.0% of revenue. Every figure is computed directly from UTMD's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $39M | 29.6% | 29.3% |
| FY2024 | $41M | 33.2% | 33.9% |
| FY2023 | $50M | 33.4% | 33.1% |
| FY2022 | $52M | 37.9% | 31.5% |
| FY2021 | $49M | 38.5% | 30.1% |
How does UTMD compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.